A delta opioid receptor lacking the third cytoplasmic loop is generated by atypical mRNA processing in human...

Area of Science:

• Molecular biology
• Oncology
• Neuroscience

Background:

• Delta opioid receptors (DOR) are G protein-coupled receptors involved in various physiological processes.
• Aberrant receptor expression and function are implicated in cancer development and progression.

Purpose of the Study:

• To investigate the presence and characteristics of delta opioid receptors in human melanomas.
• To determine if specific DOR variants are associated with melanoma malignancy.

Main Methods:

• Reverse transcription polymerase chain reaction (RT-PCR) to detect DOR mRNA.
• Radioligand binding assays to quantify DORs.
• Analysis of mRNA processing and splice variants.

Main Results:

• Delta opioid receptors were identified in human melanomas.
• A shorter DOR variant, lacking 144 bp from the third exon (third cytoplasmic domain), was consistently detected in all tumors.
• This variant resulted from atypical mRNA processing, resembling transposon excision, and was absent in normal melanocytes and brain tissue.
• The short DOR variant was also found in a human neuroblastoma cell line.

Conclusions:

• The short delta opioid receptor variant appears to be specifically associated with malignancy.
• Its unique processing suggests a potential role in melanoma development or progression.
• Further research is warranted to elucidate the functional implications of this variant in cancer.